Holding(s) In Company
Blood Cancer United, Inc., through its subsidiary TAP BCU Faron, LLC, has notified Faron Pharmaceuticals Ltd of a decrease in its holdings, resulting in a 3.47% stake in voting rights, representing 7,037,426 shares. This notification was made on May 14, 2026, following the threshold crossing on April 15, 2026. The company clarified that this percentage includes treasury shares, and would be 3.527% if treasury shares were excluded.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | May 18, 2026 at 09:00:00 EEST |
TR-1: Standard form for notification of major holdings
- Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
| Non-UK issuer | X |
- Reason for the notification (please mark the appropriate box or boxes with an “X”)
| An acquisition or disposal of voting rights | X |
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii : Decrease of holdings
Details of person subject to the notification obligation iv
| Name | Blood Cancer United, Inc. |
| City and country of registered office (if applicable) | Washington, D.C., United States of America |
Full name of shareholder(s) (if different from 3.) v
Name TAP BCU Faron, LLC
| City and country of registered office (if applicable) | Newark, Delaware, United States of America |
| 5. Date on which the threshold was crossed or reached vi : | 15/04/2026 |
| 6. Date on which issuer notified (DD/MM/YYYY): | 14/05/2026 |
- Total positions of person(s) subject to the notification obligation
| Resulting situation on the date on which threshold was crossed or reached | 3.47% | 3.47% | 7,037,426 |
| Position of previous notification (if applicable) | |||
| A: Voting rights attached to shares | |||
| Class/type of shares ISIN code (if possible) | Number of voting rights ix | % of voting rights | |
| Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) |
| FI4000153309 | 7,037,426 | 3.47% | |
| SUBTOTAL 8. A | 7,037,426 | 3.47% | |
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
SUBTOTAL 8.B.2
| Blood Cancer United, Inc. 100% owner of TAP BCU, LLC | 0% | 0% |
| TAP BCU, LLC. 100% owner of TAP BCU Faron, LLC | 0% | 0% |
| TAP BCU Faron, LLC, | 3.47% | 3.47% |
10 . In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
Additional information xvi
Providing information directly to the Company as a result of meeting the threshold in the Company’s Arti-cles of Association (does not meet the AIM regulatory notification threshold). Gordon G. Miller, Jr. (“JR Miller”), Executive Vice President & Chief Financial Officer Blood Cancer United, Inc. and authorized controlling person with respect to: Blood Cancer United, Inc., TAP BCU, LLC and TAP BCU Faron, LLC TAP BCU Faron, LLC, c/o Blood Cancer United, Inc. 1201 15th Street N.W., Suite 410, Washington, D.C. 20005 U.S.A. +1.860.488.1774 Jr.Miller@bloodcancerunited.org 3.47% of shares and voting rights is as per Faron Pharmaceuticals Ltd. request to include Treasury Shares in the denominator. The percentage is 3.527% if exclude Treasury Shares.
| Place of completion | Blood Cancer United, Inc. Washington, D.C. U.S.A. |
| Date of completion | 14/05/2026 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.